Clinical Trial Update: Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning [Phase 2]

View source ↗

Summary

Phase 2 trial in multiple myeloma patients aged 65 or younger who have at least 50% response after autologous transplant is evaluating an allogeneic transplant …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Myeloma | Phase 2 | Status: COMPLETED